Efficacy and safety of HRS-7535, an oral small-molecule GLP-1 receptor agonist, in patients with diabetic kidney disease (SOLID-DKD): a randomised, double-blind, placebo-controlled, phase 2 trial.
An oral GLP-1 drug reduced kidney protein leakage by nearly a third in diabetics with kidney disease, adding hope for protecting kidneys beyond current standard treatments.
HRS-7535 90mg reduced UACR by 32% (placebo-corrected) at 16 weeks in DKD patients on intensive background therapy (SGLT2i + finerenone); HbA1c improved -1.09%, body weight -2.95%; safety consistent with GLP-1RA class; supports phase 3 renal outcome trial. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- randomised_controlled_trial
- Category
- cardiovascular_metabolic
- Maturity
- Potentially Practice-Changing
- Journal
- EClinicalMedicine
Why it surfaced
First phase 2 RCT of oral small-molecule GLP-1RA in DKD; phase 2 RCT design with robust endpoints, novel agent class, very high unmet clinical need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.